A Phase 3 clinical trial of VVN461 in U.S.
Latest Information Update: 17 Dec 2024
Price :
$35 *
At a glance
- Drugs VVN 461 (Primary)
- Indications Postoperative inflammation
- Focus Therapeutic Use
- 17 Dec 2024 New trial record
- 03 Dec 2024 According to a VivaVision media release, the positive topline results of the phase 2 trial of VVN461 for Post-Operative Inflammation following Cataract Surgery provide a strong foundation to advance towards a Phase 3 clinical trial of VVN461 in the U.S.